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Combination therapyYAP and TAZ oncoproteins confer malignancy and drug resistance to various cancer types. We
screened for small molecules that inhibit the nuclear localization of YAP/TAZ. Dasatinib, statins
and pazopanib inhibited the nuclear localization and target gene expression of YAP and TAZ. All
three drugs induced phosphorylation of YAP and TAZ, and pazopanib induced proteasomal degrada-
tion of YAP/TAZ. The sensitivities to these drugs are correlated with dependence on YAP/TAZ in
breast cancer cell lines. Combinations of these compounds with each other or with other
anti-cancer drugs efﬁciently reduced cell proliferation of YAP/TAZ-dependent breast cancer cells.
These results suggest that these drugs can be therapeutics and chemosensitizers for
YAP/TAZ-dependent breast cancers.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
YAP and TAZ are transcriptional co-activators involved in tissue
growth and stem cell maintenance in normal tissue through bind-
ing to TEADs. They are regulated through phosphorylation by the
Hippo pathway, leading to inhibition of the nuclear translocation
and the proteasomal degradation [1]. The Hippo pathway is acti-
vated by cellular density [2–4], soluble factors via GPCR [5,6],
and actin cytoskeleton organization [7,8]. YAP and TAZ activations
are also implicated in the tumorigenesis and malignancy of various
cancers including breast [9], colon [10], lung [11], liver [12], and
mesothelioma [13]. TAZ is associated with the maintenance of
breast cancer stem cells and drug resistance [14]. Therefore, YAP
and TAZ play causative roles in carcinogenesis and cancer progres-
sion, and inactivation of YAP and TAZ by small molecules is a
promising strategy for therapeutics of various cancers with their
activation [15].In drug discovery, one of the successful strategies is the
exploitation of established drugs that have already been approved
for treatment of other cancers or non-cancerous diseases (i.e., drug
repositioning, drug repurposing, or indication switch). The major
advantage of this approach is that the pharmacokinetic, pharmaco-
dynamics and toxicity proﬁles of these drugs are well known,
making their rapid shifts to clinical trials possible [16,17].
In this study, we screened for small molecules which inacti-
vate YAP and TAZ from drugs with known targets for the drug
repositioning against breast cancer. We found that dasatinib, sta-
tins, and pazopanib inhibited their nuclear localization and
TEAD-dependent transcription, and induced YAP/TAZ phosphory-
lation. Pazopanib induced proteasomal degradation of YAP and
TAZ. Furthermore, we explored the possibility of chemotherapy
with them for breast cancer, and found that the sensitivities to
these compounds are correlated with the dependence on YAP
and TAZ in these cell lines. Combination of the YAP/TAZ
inhibitors or of those with anti-cancer agents efﬁciently
suppressed the breast cancer cell growth. Our ﬁndings thus
opened the window for the application of dasatinib, statins,
and pazopanib, clinically used drugs, for breast cancers with
activation of YAP and TAZ.
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2.1. Cell culture and treatments
MDA-MB-231, MDA-MB-453, HBC-4, HBC-5, MCF-7, BSY-1,
ZR-75-1, and SKBR-3 breast cancer cell lines were maintained in
RPMI-1640 containing 10% FBS and penicillin/streptomycin.
HEK293 was maintained in Dulbecco’s modiﬁed Eagle medium
containing 10% FBS and penicillin/streptomycin. Dasatinib was
purchased from JS Research Chemicals Trading Co. Fluvastatin,
doxorubicin, and paclitaxel were purchased from Wako Pure
Chemicals. Geranylgeranyl diphosphate (GGPP), farnesyl diphos-
phate (FPP), GGTI-286, and FTI-276 were purchased from Sigma.
MG-132 was purchased from Merck Mllipore, and pazopanib from
ChemieTek.
2.2. Antibodies
For immunoﬂuorescence, 1/200 rabbit anti-YAP antibody
(H-125, Santa Cruz), 1/400 rabbit anti-YAP/TAZ antibody (D24E4,
Cell Signaling), 1/200 phalloidin-AlexaFluor 594 (Life
Technologies), and 1/1000 anti-rabbit IgG-AlexaFluor 488 conju-
gate (Life Technologies) were used. For immunoblot, 1/3000 rabbit
anti-YAP antibody (H-125, Santa Cruz), 1/3000 rabbit anti-TAZ
antibody (#2149, Cell Signaling), 1/3000 rabbit anti-YAP/TAZ
antibody (D24E4, Cell Signaling), 1/10,000 mouse anti-GAPDH
antibody (6C5, Millipore), 1/5000 anti-mouse IgG-HRP (GE
Healthcare), and 1/5000 anti-rabbit IgG-HRP (GE Healthcare), were
used. Antibodies for Western blot were diluted in Can Get Signal
reagents (Toyobo). Western blot using standard SDS–PAGE gel or
gels containing Phos-tag-acrylamide (SuperSep Phos-tag, Wako)
was performed as previously described [18].
2.3. Screening of the inhibitors inhibiting nuclear localization of YAP
MDA-MB-231 cells (10,000–15,000 cells) were inoculated in a
lclear imaging plate (Corning) and 24 h later, 10 lM chemicals
in a SCADS inhibitor kit (provided by the Screening Committee of
Anticancer Drugs, Japan) was added and incubated for 6 h. Cells
were ﬁxed with 4% paraformaldehyde and immunostained with
anti-YAP antibody as described below.
2.4. Immunoﬂuorescence and imaging
Paraformaldehyde-ﬁxed cells were permeabilized with 0.3%
TritonX-100 in PBS and blocked with 3% FBS in PBST for 30 min.
They were then incubated with anti-YAP antibody at 4 C overnight
and washed with PBS three times. Cells were incubated with
anti-rabbit IgG-Alexa Fluor 488 for 1 h at room temperature, and
washed with PBS three times. For confocal microscopy, cells were
mounted in Prolong Gold reagent containing 10 lg/ml Hoechst
33342 (Life Technologies). When appropriate, cells were stained
with phalloidin-Alexa Fluor 594 (Life Technologies) prior to mount-
ing. Images were obtained with an FV1000-D confocal microscope
equipped with a 40 objective lens using FV10-ASW software
(Olympus). For screening of small molecules, PBS containing
10 lg/ml Hoechst 33342 was added and images were obtained by
IN Cell Analyzer 2000 (GE Healthcare) using a 40 objective lens.
2.5. Reporter assay
8xGTIIC-luciferase was obtained from Addgene (Addgene
#34615). MDA-MB-231 cells were transfected with 1.4 lg of
8xGTIIC-luciferase plasmid and 50 ng of pRL-CMV (Promega) by
using lipofectamine 2000 (Life Technologies) or Viafecttransfection reagent (Promega) as previously described [7]. After
24 h, cells were treated with chemicals for 18 h. Luciferase activi-
ties were measured using the Dual-Luciferase Reporter Assay
System (Promega) according to the manufacturer’s instructions.
2.6. Quantitative real time PCR
Total RNA was prepared with ISOGEN (Nippon Gene) and cDNA
was synthesized with ReverTra Ace qPCR RTmaster mix with gDNA
remover (TOYOBO). Real time PCR was performed with QuantiTect
SYBR Green PCR Master Mix (Qiagen) using the Eco Real Time PCR
system (Illumina). The sequences of PCR primers for CTGF and
GAPDH were as follows; CTGF-F: AGGAGTGGGTGTGTGACGA,
CTGF-R: CCAGGCAGTTGGCTCTAATC, GAPDH-F: AGCCACATCGCTC-
AGACAC, GAPDH-R: GCCCAATACGACCAAATCC.
2.7. RNAi
siRNA transfection was performed using Lipofectamine
RNAiMAX (Life Technologies) according to the manufacturer’s
instructions. The siRNA sequence is listed as followed; siYAP:
GACAUCUUCUGGUCAGAGAUU, siTAZ: ACGUUGACUUAGG-
AACUUUUU [14].
2.8. MTT assay
MTT assay was performed as previously described [18]. 3000–
10,000 cells suspended in RPMI-1640 containing 1% FBS were
seeded on 96 well plates. Fifteen ll of medium containing drugs
was added, and cells were incubated for 4 days.
2.9. Colony formation assay
MDA-MB-231 or MCF-7 cells (1000–2000 cells per well) were
seeded on 24 well plates and treated with inhibitors for 10 days.
Cells were ﬁxed with 4% formaldehyde and stained with 0.5%
crystal violet.
3. Results
3.1. Dasatinib, ﬂuvastatin, and pazopanib inhibit the function of YAP/
TAZ transcriptional co-activator
To identify drugs targeting YAP and TAZ, we performed
image-based screening for small molecules which inhibit their
nuclear localization using MDA-MB-231 breast cancer cell line.
MDA-MB-231 harbors homozygous mutation in NF2, which posi-
tively regulates the Hippo pathway; therefore, YAP and TAZ are
constitutively activated in this cell line [19]. We screened about
400 chemicals with known targets from SCADS inhibitor kit (pro-
vided by the Screening Committee of Anticancer Drugs, Japan)
which consists of classical anti-cancer agents, kinase inhibitors,
metabolic pathway inhibitors, and signaling pathway inhibitors,
including FDA-approved drugs [20]. MDA-MB-231 cells were trea-
ted with chemicals and nuclear localization of YAP was evaluated
by immunoﬂuorescence. Chemicals which induced nuclear exclu-
sion of YAP were treated as positive. We found that thiazovivin,
dasatinib, lovastatin, cucurbitacin I, and pazopanib inhibited the
nuclear localization of YAP (Fig. 1A). Among them, dasatinib,
statins, and pazopanib are approved as clinically used drugs, and
we therefore analyzed them further. We found that dasatinib,
ﬂuvastatin, and pazopanib inhibited nuclear localization of YAP
and TAZ in the nanomolar to micromolar range, although the effect
of pazopanib on the nuclear localization of YAP/TAZ was relatively
weak compared to the other two drugs (Fig. 1B). They also
Fig. 1. Dasatinib, ﬂuvastatin, and pazopanib inhibit the function of YAP/TAZ transcriptional co-activator. (A) Identiﬁcation of small molecule agents which inhibit the nuclear
localization of YAP. MDA-MB-231 cells were treated with a chemical library for 8 h. YAP was immunostained. Red: DNA, green: YAP. Each agent was used at 10 lM. (B)
Dasatinib, ﬂuvastatin, and pazopanib inhibited the nuclear localization of YAP and TAZ. MDA-MB-231 cells were treated with inhibitors for 8 h and YAP and TAZ were
visualized by immunoﬂuorescence. (i) Representative images of immunoﬂuorescence. Bar represents 10 lm. (ii) Cells with nuclear localization of YAP and TAZ were counted.
At least 75 cells were counted for each sample. Data represents mean and standard deviation from three independent experiments. (C) Inhibition of TEAD-dependent
promoter activity by dasatinib, ﬂuvastatin, and pazopanib. MDA-MB-231 cells were transfected with 8xGTIIC-luciferase TEAD reporter plasmid with pRL-CMV control
plasmid, and treated with inhibitors overnight. Relative luciferase activity (8xGTIIC-luciferase/Renilla luciferase) was measured. Data represents mean and standard deviation
from at least three independent experiments. *P < 0.02. (D) Inhibition of endogenous target genes of YAP and TAZ by dasatinib, ﬂuvastatin, and pazopanib. MDA-MB-231 cells
were treated with inhibitor for 18 h and total RNA was prepared. CTGF mRNA was quantiﬁed by quantitative RT-PCR. Data represents mean and standard deviation from at
least three independent experiments. *P < 0.02. (E) Dasatinib, ﬂuvastatin, and pazopanib activate the Hippo pathway. (i) Induction of phosphorylation of YAP and TAZ by
dasatinib, ﬂuvastatin and pazopanib. MDA-MB-231 cells were treated with inhibitors for 8 h. Whole cell extract was analyzed by SDS–polyacrylamide gel containing Phos-tag
acrylamide. Asterisks show phosphorylated YAP and TAZ. Data is representative of at least three independent experiments. (ii) Degradation of YAP and TAZ by pazopanib is
proteasome-dependent. MDA-MB-231 cells were treated with pazopanib for 8 h in the presence or absence of 10 lM MG132. Whole cell extract was analyzed by Western
blot. Data is representative of at least three independent experiments.
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We found that they also reduced the transcripts of CTGF, whose
transcription is dependent on YAP/TAZ (Fig. 1D). Dasatinib and ﬂu-
vastatin are known to change actin dynamics, and this leads to
phosphorylation of YAP/TAZ [19]. Dasatinib inhibits SRC and
affects YAP nuclear localization [21]. Statins inhibit HMG-CoA
reductase and lead to impaired geranylgeranylation of RHOA,
resulting in the inactivation of YAP/TAZ as reported recently
[22,23]. We reproduced the geranylgeranylation-dependent inacti-
vation of YAP/TAZ by ﬂuvastatin, as the simultaneous addition of
geranylgeranyl diphosphate (GGPP), but not farnesyl diphosphate
(FPP), with ﬂuvastatin canceled the effect of ﬂuvastatin
(Supplementary Fig. S1). We also found that the direct inhibition
of protein geranylgeranylation recapitulated phosphorylation of
YAP (Supplementary Fig. S1). These results conﬁrmed the
RHOA-dependent inactivation of YAP/TAZ by statins [22,23].
Pazopanib inhibits VEGFR and PDGFR signaling. VEGF signaling
induces activation of RHOA in cervical cancer cells as well as vascu-
lar endothelial cells [24,25]. Inhibition of VEGF signaling is known to
impair the activation of SRC and FAK, leading to impaired activationof RHOA. PDGF signaling also induced activation of RHOA [26].
MDA-MB-231 is known to express VEGFR2, a VEGFR familymember
[27] and PDGFR [28]. We hypothesized that the phosphorylation of
YAP/TAZ accounted for the inhibition of YAP/TAZ nuclear localiza-
tion by pazopanib. Therefore, we examined whether pazopanib
induced the phosphorylation of YAP and TAZ, and found the increase
in the ratio of phosphorylated YAP and TAZ by this drug by pazopa-
nib similar to that by dasatinib and ﬂuvastatin (Fig. 1E i), suggesting
that pazopanib also induces YAP/TAZ phosphorylation. We further
noted that treatment of cells with pazopanib reduced the total
amount of YAP/TAZ in the cell. This reductionwas canceled by a pro-
teasome inhibitor, MG-132, (Fig. 1E ii) suggesting that pazopanib
facilitates degradation of YAP/TAZ by the ubiquitin–proteasome
system as previously described [29].
3.2. YAP/TAZ-dependent breast cancer cell lines are sensitive to
dasatinib, ﬂuvastatin, and pazopanib
YAP and TAZ activation is frequently observed in various can-
cers and is associated with resistance to anti-cancer agents,
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hypothesized that dasatinib, statins, and pazopanib are effective
for YAP/TAZ-dependent breast cancer cells and therefore addressed
whether they suppressed the breast cancer cell growth. The
response to these drugs was different among cell lines, and we
found that MDA-MB-231 was most sensitive to these inhibitors.
On the other hand, some cell lines (MCF-7, for example), and
HEK293 (human embryonic kidney cell), were resistant to them
(Fig. 2A). Examining the level of YAP/TAZ-dependent transcription
in these cell lines, we found that MDA-MB-231 showed the highest
YAP/TAZ-dependent transcriptional activity among eight breast
cancer cell lines (Fig. 2B), which is consistent with the NF2 muta-
tion in this cell line [19]. MDA-MB-231 expressed higher YAP
and TAZ, and phosphorylation of YAP and TAZ was lower than that
in other cell lines (Fig. 2C). We hypothesized that the activation
and dependence of YAP and TAZ is one determinant of the
effectiveness of these YAP/TAZ inhibitors and examined the colony
formation assay using cells treated with YAP and TAZ siRNA. Colony
formation was dramatically reduced when both YAP and TAZ were
depleted in MDA-MB-231 (Fig. 2D). Therefore, cell growth of
MDA-MB-231 is YAP/TAZ-dependent. On the other hand, some cell
lines which are resistant to the agents, including MCF-7, are also
resistant to silencing of YAP and TAZ by siRNA (Fig. 2D), suggestingFig. 2. YAP/TAZ-dependent breast cancer cell lines are sensitive to dasatinib, ﬂuvasta
ﬂuvastatin, and (iii) pazopanib. Cells were treated with drugs for 4 days. Viability was me
Data is representative of at least three independent experiments. HEK293 (black lin
transcription in breast cancer cell lines. Cells were transfected with 8xGTIIC-luciferase a
represents mean and standard deviation from triplicate. Data is representative of at leas
lines. Asterisks show phosphorylated YAP and TAZ. (D) Dependence of cell growth on YA
well plates. Colony formation was measured by crystal violet. Data is representative ofMCF-7 is a YAP/TAZ-independent cell line. In summary, we con-
cluded that there was a correlation between the dependence of
YAP/TAZ in breast cancers and the sensitivities to dasatinib, ﬂuvas-
tatin, and pazopanib.
3.3. Combination of dasatinib, ﬂuvastatin and pazopanib efﬁciently
reduced the viability of MDA-MB-231
Although dasatinib, ﬂuvastatin, and pazopanib can inactivate
YAP and TAZ in breast cancers, their doses were relatively high
compared to clinically relevant ones. Higher blood concentration
of these drugs can be a risk factor for adverse effects. Reduced con-
centrations of them to cancer cells are relevant in terms of drug
safety. Their use in combination is a feasible approach for this.
We ﬁrst combined the dasatinib, ﬂuvastatin, and pazopanib for
MDA-MB-231 cell line, and found that their combinations
efﬁciently reduced viability of the cells (Fig. 3A). Although emergence
of the colonies was not largely affected, the colony sizes were
efﬁciently reduced by the combination of these inhibitors (Fig. 3B).
Then again, single agents or their combinations did not reduce
colony formation of MCF-7, YAP/TAZ-independent cell line (Fig. 3B).
These results suggested that combinations of these agents are one
of the efﬁcient strategies against YAP/TAZ-dependent cell lines.tin, and pazopanib. (A) Sensitivity of breast cancer cell lines to (i) dasatinib, (ii)
asured by MTT assay. Data represents mean and standard deviation from triplicate.
e) was used as normal cell control. (B) Activation states of YAP/TAZ-dependent
nd pRL-CMV vector. Promoter activity was measured 2 days after transfection. Data
t two independent experiments. (C) Expression of YAP and TAZ in breast cancer cell
P and TAZ. Cells were transfected with siRNA for YAP and TAZ and were diluted in 6
at least two independent experiments.
Fig. 3. Combination of dasatinib, ﬂuvastatin and pazopanib efﬁciently reduced the viability of MDA-MB-231. (A) Combination therapy using dasatinib, ﬂuvastatin, and
pazopanib for MDA-MB-231. (i) Fluvastatin in combination with dasatinib. (ii) Pazopanib with dasatinib. (iii) Pazopanib with ﬂuvastatin. Cells were treated with inhibitors for
4 days and viability was measured by MTT assay. Data represents mean and standard deviation of triplicate. Data is a representative of at least three independent
experiments. (B) Colony formation reduced by the combination of dasatinib, ﬂuvastatin, and pazopanib in MDA-MB-231. (i) MDA-MB-231 and (ii) MCF-7 cells were treated
with the combination of inhibitors (dasa: dasatinib, ﬂuva: ﬂuvastatin, pazo: pazopanib) for 7 or 10 days. Colony formation was determined by staining with crystal violet.
Data is representative of three independent experiments.
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dependent cancer cells to doxorubicin and paclitaxel
TAZ confers the resistance to paclitaxel and doxorubicin, and
its depletion leads to sensitization of cells to these anti-cancer
drugs in breast cancer cells [9,32]. Therefore, we hypothesized
that dasatinib, ﬂuvastatin, and pazopanib can act as
chemosensitizers for YAP/TAZ-dependent breast cancer cells.
MDA-MB-231 was then treated with paclitaxel or doxorubicin
together with dasatinib, ﬂuvastatin, or pazopanib. We found
that some combination of YAP/TAZ inhibitors with these
anti-cancer agents synergistically reduced cell viability
(Fig. 4A). Colony formation was also signiﬁcantly reduced by
the combination therapies (Fig. 4B).
Chemosensitizing effects were not consistently observed when
MCF-7, whose cell growth is YAP/TAZ-independent, was treated
with these combinations (Fig. 4C). Colony formation of this cell
line was also not affected by the combination of agents
(Fig. 4D). These results suggested that dasatinib, ﬂuvastatin, and
pazopanib can be chemosensitizers for YAP/TAZ-dependent breast
cancer cells.
4. Discussion
YAP and TAZ are emerging targets for breast cancer treatment.
In this study we identiﬁed the clinically used drugs, dasatinib, sta-
tins, and pazopanib as small molecule agents which inhibit the
nuclear localization of YAP/TAZ transcriptional co-activators.
These agents are effective for YAP/TAZ-dependent breast cancer;their combination increased the efﬁcacy. Furthermore, they can
also act as chemosensitizers of doxorubicin and paclitaxel. We pro-
posed them as candidate chemotherapeutic agents for
YAP/TAZ-dependent breast cancers.
Thiazovivin, cucurbitacin I, dasatinib, ﬂuvastatin, and pazopa-
nib inhibit nuclear localization of YAP/TAZ, and activate the
Hippo pathway. Thiazovivin is a RHO-kinase inhibitor and modu-
lates actin cytoskeletal dynamics. Inhibition of RHO-kinase is
known to inhibit nuclear localization of YAP/TAZ [19], indicating
the validity of our screening. Cucurbitacin I is a plant poison and
indirectly affects actin dynamics [33]. Changes in the cytoskeletal
dynamics can activate YAP/TAZ as previously reported [7].
Among them, we focused on three FDA-approved drugs.
Dasatinib, a SRC inhibitor, changes actin dynamics, leading to
decrease in nuclear localization of YAP and TAZ [21]. Recent papers
have shown that statins inhibit nuclear localization of YAP/TAZ via
reduction of geranylgeranylation of RHO family GTPases, followed
by phosphorylation [22,23]. In addition to them, we found that
pazopanib, a multikinase inhibitor, inhibited the nuclear localiza-
tion of YAP/TAZ, leading to reduced transcription. Pazopanib also
induced phosphorylation of YAP, similar to that by dasatinib or ﬂu-
vastatin (Fig. 1E). Pazopanib is known as a multikinase inhibitor,
and mainly targets VEGFR and PDGFR. Previous studies revealed
that VEGFR2 and PDGFR are expressed in MDA-MB-231 [27,34–
36], and that their signalings are involved in migration and cell
growth [34,37]. In vascular endothelial cells, VEGFR signaling
affects actin ﬁlament dynamics through the RHO/ROCK pathway
in vascular endothelial cells [38]. Thus, inhibition of VEGFR2
in MDA-MB-231 may inﬂuence cytoskeletal rearrangements,
Fig. 4. Dasatinib, ﬂuvastatin, and pazopanib sensitize YAP/TAZ-dependent cancer cells to doxorubicin and paclitaxel. (A) Combination therapy with doxorubicin and
paclitaxel with (i) dasatinib, (ii) ﬂuvastatin, or (iii) pazopanib. Cells were treated with dasatinib, ﬂuvastatin, or pazopanib in combination with doxorubicin or paclitaxel for
4 days. Viability was measured by MTT assay. Data represents mean and standard deviation from triplicate, and data is representative of at least three independent
experiments. *P < 0.02. N.S.: not signiﬁcant. (B) Colony formation of MDA-MB-231 cells treated with dasatinib, ﬂuvastatin, and pazopanib in combination with doxorubicin or
paclitaxel. MDA-MB-231 cells were treated with the combination of inhibitors (dasa: dasatinib, ﬂuva: ﬂuvastatin, pazo: pazopanib, dox: doxorubicin, pac: paclitaxel) for
10 days. Colony formation was determined by staining with crystal violet. Data is representative of two independent experiments. (C) Effect of (i) dasatinib, (ii) ﬂuvastatin,
and (iii) pazopanib as chemosensitizers in MCF-7, YAP/TAZ-independent cell line. Viability was measured by MTT assay. Data represents mean and standard deviation from
triplicate, and data is representative of at least two independent experiments. (D) Colony formation of MCF-7 cells treated with dasatinib, ﬂuvastatin, and pazopanib in
combination with doxorubicin or paclitaxel. MCF-7 cells were treated with the combination of inhibitors (dasa: dasatinib, ﬂuva: ﬂuvastatin, pazo: pazopanib, dox:
doxorubicin, pac: paclitaxel) for 7 days. Colony formation was determined by staining with crystal violet. Data is representative of three independent experiments.
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induced the proteasome-dependent degradation of YAP and TAZ,
which was not prominent in the cells treated with dasatinib andﬂuvastatin (Fig. 1E). Pazopanib more strongly induced proteasomal
degradation than dasatinib or ﬂuvastatin. Although further study is
required to know the precise mechanisms of proteasomal
548 Y. Oku et al. / FEBS Open Bio 5 (2015) 542–549degradation of YAP/TAZ by pazopanib, it might exemplify a unique
class of Hippo pathway activators.
We found that the efﬁcacy of dasatinib, ﬂuvastatin, and pazopa-
nib is correlated with the dependency on YAP/TAZ in breast cancer
cell lines. MDA-MB-231 exhibited higher YAP/TAZ-dependent
transcriptional activity and its cell growth was
YAP/TAZ-dependent (Fig. 2). This cell line was sensitive to these
agents, whereas the cell line with low dependence on YAP/TAZ,
MCF-7, for example, was resistant to them (Fig. 2E). We further
showed that the combination of the identiﬁed compounds was
effective for MDA-MB-231 (Fig. 3). YAP/TAZ expression is associ-
ated with poor prognosis in many cancers, including breast cancer
[9,11,39]. YAP/TAZ is also associated with cancer stem cell traits in
breast cancer cells [14]; therefore, these agents might be effective
in YAP/TAZ-dependent cancers. We also found that dasatinib, ﬂu-
vastatin, and pazopanib sensitize MDA-MB-231 to doxorubicin
and paclitaxel. YAP/TAZ is associated with drug resistance to clas-
sical chemotherapeutics [9,32,40]. Combination therapies efﬁ-
ciently reduced the viability of MDA-MB-231 (Fig. 4). Drug
resistance is a bottleneck for anti-cancer therapy, and reversing
drug resistance to susceptibility is an attractive strategy. The
agents identiﬁed in this study are effective against
YAP/TAZ-dependent cell line (Fig. 2). In recent molecular targeted
approaches in cancer therapeutics, the stratiﬁcation of patients
with biomarkers is important. Expression or activation status of
YAP/TAZ might be a predictor for these drugs, and such stratiﬁca-
tion might be important for anti-YAP/TAZ therapy. Our ﬁndings
can offer an alternative regimen for the treatment of breast cancer
using clinically approved drugs.
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